Objective:
To provide an overview of the evolving treatment landscape for Dry Eye Disease (DED) and ocular surface disease (OSD), emphasizing the critical role of personalized treatment selection in improving patient outcomes.
Key Findings:
- DED affects 5% to 50% of individuals globally, significantly impacting quality of life and daily functions.
- The introduction of anti-inflammatory treatments has transformed DED management since 2003, improving patient outcomes.
- A stepwise approach to treatment is recommended, starting with basic therapies and escalating as needed, supported by diagnostic tools.
- New treatments like Miebo and Vevye offer innovative mechanisms for symptom relief and ocular surface healing, enhancing patient care.
- Intranasal sprays like Tyrvaya provide alternatives for patients struggling with eye drops, expanding treatment options.
Interpretation:
The expanding range of DED treatments offers opportunities for personalized care but requires clinicians to navigate complexity in prescribing.
Limitations:
- The article does not provide extensive clinical trial data for all mentioned treatments, particularly regarding long-term efficacy.
- Potential side effects of newer therapies are briefly mentioned but not deeply explored, warranting further investigation.
Conclusion:
The treatment landscape for DED is rapidly evolving, necessitating a tailored approach to optimize patient outcomes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.